A new class of PentixaFor- and PentixaTher-based theranostic agents with enhanced CXCR4-targeting efficiency
Theresa Osl, Alexander Schmidt, Markus Schwaiger, Margret Schottelius, Hans‐Jürgen Wester
Abstract
Non-invasive PET imaging of CXCR4 expression in cancer and inflammation as well as CXCR4-targeted radioligand therapy (RLT) have recently found their way into clinical research by the development of the theranostic agents [ 68 Ga]PentixaFor (cyclo(D-Tyr 1 -D-[NMe]Orn 2 (AMBS-[ 68 Ga]DOTA)-Arg 3 -Nal 4 -Gly 5 ) = [ 68 Ga]DOTA-AMBS-CPCR4) and [ 177 Lu/ 90 Y]PentixaTher (cyclo(D-3-iodo-Tyr 1 -D-[NMe]Orn 2 (AMBS-[ 177 Lu/ 90 Y]DOTA)-Arg 3 -Nal 4 -Gly 5 ) = [ 177 Lu/ 90
Topics & Concepts
Class (philosophy)BiologyNanotechnologyComputational biologyComputer scienceMaterials scienceArtificial intelligenceChemokine receptors and signalingMonoclonal and Polyclonal Antibodies Researchinterferon and immune responses